MET and breast cancer: Tchou et al. tested c-Met as a potential target for CAR-T cell therapy; for this purpose, the scFv of the CD19 binding domain of a CD19-CAR molecule was substituted for that of onartuzumab, and then its effectiveness against BC cells was confirmed in vitro and in vivo [113].